Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Absci Corporation

$7.57

+0.55 (+7.86%)

D 24Pipeline Score Richly Valued Biotech · Clinical
Market Cap
795.12 M
EPS
-0.83
P/E Ratio
-
Value Trade
30.16 M
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • Revenue

    215.00 K

  • R&D Expenses

    19.27 M

  • Operating CF

    -26.31 M

  • Total Assets

    195.59 M

  • Total Liabilities

    23.62 M

  • Equity

    171.97 M

  • D/E Ratio

    12,345

-4.49 %
Week
27.5 %
1 Month
86.13 %
3 Month
84.12 %
6 Month
-75.71 %
5 Year
-75.71 %
All Time
Cash Data
Stable

  • Cash Position

    125.70 M

  • Monthly Burn

    8.77 M

  • Runway

    13.2 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 7, 2026
Overview
Volume
1.73 M
52 Week Range
2.24 - 6.72
% held by Insiders
14.5 %
% held by Institutions
75 %
Enterprise Value
673.83 M
Total Shares
150.41 M
Short %
29.54 %
Float Shares
108.60 M
Company Description
HQ: 18105 SE MILL PLAIN BLVD, VANC...
Employees:140
https://www.absci.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1 updated data readout example
ABS-101 Autoimmune / inflammatory indications (anti‑TL1A; Phase 1 safety/PKPD follow‑up)
Phase 1
—
-
-
ABS-101 Autoimmune / inflammatory indications (anti‑TL1A; Phase 1 safety/PKPD follow‑up)
Phase 1
—
-
-
ABS-101 Autoimmune / inflammatory indications (anti‑TL1A; Phase 1 safety/PKPD follow‑up)
Phase 1
—
-
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D24
Pipeline Score
$17M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 24%
Micro Cap
(rank 689 of 905)
Percentile Rank
Absci Corporation faces pipeline headwinds (24/100), with $63M risk-adjusted pipeline value, led by ABS-201 Single Dose in Androgenetic Alopecia (AGA) (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
ABS-201 Single Dose
Small molecule		Androgenetic Alopecia (AGA)Phase 1NCT0731754415% $63M RECRUITING 227 VERY_FAST C (52) Jul 1, 2028LOW_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ABSI
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ABSI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ABSI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ABSI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ABSI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ABSI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ABSI ranks across every disease it competes in
Competitive Position is a premium feature
See how ABSI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial